# US 2018/0022806 A1 · Markers of acute myeloid leukemia stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022806 A1
- Document ID: US20180022806A1
- Status: Published application
- Kind: A1
- Application number: 15/704,790
- Filed: 2017-09-14
- Published: 2018-01-25
- Earliest claimed: 2008-01-15
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Ravindra Majeti; Irving L. Weissman
- Web page: https://patentgrep.com/patent/US20180022806A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 35/02: specific for leukemia
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/30: from tumour cells
- C12N 5/0093: {Purging against cancer cells}
- C12N 5/0694: {Cells of blood, e.g. leukemia cells, myeloma cells}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/57505: of the blood, e.g. leukaemia
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/136: Screening for pharmacological compounds
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

## Claims

### Claim 1

A method for characterizing an acute myeloid leukemia from a patient, the method comprising:
contacting a patient sample with reagents specific for a differentially expressed marker or combination of markers set forth in Table 1;
quantitating the number of marker expressing cancer cells,
wherein the presence of marker expressing cancer cells is indicative of the presence of AML stem cells (AMLSC).

### Claim 2 (depends on 1)

The method of claim 1, wherein the quantitating is performed by flow cytometry.

### Claim 3 (depends on 1)

The method of claim 1, wherein the quantitating is performed by immunohistochemistry.

### Claim 4 (depends on 1)

The method of claim 1, wherein the sample is a blood sample.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient has been diagnosed as having AML.

### Claim 6 (depends on 5)

The method of claim 5, wherein the patient is undergoing treatment for AML.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said patient is a human.

### Claim 8 (depends on 1)

The method of claim 1, wherein the marker is selected from CD97, CD99, CD180 and TIM3.

### Claim 9 (depends on 1)

A kit for use in the method of claim 1.

### Claim 10

A method of screening a candidate chemotherapeutic agent for effectiveness against an AMLSC, the method comprising:
contacting an AMLSC expressing a polypeptide set forth in Table 1 with a candidate agent, and
determining the effectiveness of said agent against said AMLSC.

### Claim 11

A method of targeting or depleting AML cancer stem cells, the method comprising contacting reagent blood cells with an agent that specifically binds a marker or combination of markers set forth in Table 1 in order to target or deplete AMLSC.

### Claim 12 (depends on 11)

The method of claim 11, wherein the agent is an antibody.

### Claim 13 (depends on 11)

The method of claim 11, wherein the the marker is selected from CD97, CD99, CD180 and TIM3.

### Claim 14 (depends on 12)

The method of claim 12, wherein the agent is a bispecific antibody that binds two markers set forth in Table 1.

### Claim 15 (depends on 11)

A therapeutic formulation for use in the method of claim 11.

### Claim 16

A method for the diagnosis or staging of AML, the method comprising:
determining the upregulation of expression of a genetic sequence selected from those listed in Table 1.

### Claim 17 (depends on 16)

The method according to claim 16 wherein said determining comprises detecting increased or decreased amounts of mRNA or polypeptide in a sample of cancer cells.

### Claim 18 (depends on 16)

The method according to claim 16, wherein expression is determined by hybridization to an array.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said array comprises two or more sequences set forth in Table 1.
